Sintx Technologies, Inc. (SINT) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Sintx Technologies, Inc. (SINT) Healthcare & Pipeline Overview

Sintx Technologies, Inc. is an advanced materials enterprise specializing in silicon nitride for biomedical, industrial, and antipathogenic applications. Leveraging its proprietary material science, the company develops solid, porous, and coated silicon nitride products, focusing on innovation within the medical device sector from its Salt Lake City headquarters.

What Is the Investment Thesis for SINT?

Sintx Technologies, Inc. is positioned as an advanced materials enterprise focusing on silicon nitride for medical and industrial applications, particularly in orthopedic and spinal implants. The company's core value proposition stems from silicon nitride's inherent antibacterial properties, which could significantly reduce infection rates in medical devices, a critical differentiator in the competitive healthcare market. With a market capitalization of $9.60M, Sintx operates with a Beta of 0.62, suggesting lower volatility relative to the broader market. However, the company faces significant financial challenges, evidenced by a profit margin of -1711.6% and a gross margin of -32.7%, indicating substantial operational losses. Growth catalysts include securing regulatory approvals for new silicon nitride product applications and gaining market share against established players using traditional materials. The ability to effectively commercialize its diverse portfolio, including solid, porous, and coated silicon nitride, alongside advanced composites, will be crucial. Investors should monitor the company's progress in clinical adoption, intellectual property development, and its path towards profitability, as these factors will dictate long-term value creation.

Based on FMP financials and quantitative analysis

SINT Key Highlights

Market Capitalization: $0.01 billion, indicating a micro-cap company operating in the medical devices sector.

• Profit Margin: -1711.6%, reflecting significant net losses relative to revenue, underscoring the company's early-stage commercialization or high R&D expenditures.
• Gross Margin: -32.7%, suggesting that the cost of goods sold currently exceeds revenue, pointing to challenges in production efficiency or pricing power.
• Beta: 0.62, indicating lower volatility compared to the broader market, which may appeal to investors seeking less market-sensitive assets.
• Dividend Yield: None, as the company does not currently distribute dividends to shareholders, consistent with its growth-oriented stage and negative profitability.

Who Are SINT's Competitors?

SINT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SINT's Key Strengths?

Proprietary expertise in silicon nitride material science and manufacturing.

• Silicon nitride's inherent antibacterial properties, a key differentiator for medical implants.
• Diverse product portfolio including solid, porous, powder, and composite silicon nitride materials.
• Established presence in the advanced materials sector since 1996.

What Are SINT's Weaknesses?

Significant negative profit margin (-1711.6%) and gross margin (-32.7%) indicating substantial losses.

• Small employee base (20 employees) which may limit scalability and extensive market reach.
• Reliance on a single core material (silicon nitride) for most product lines.
• Potential challenges in gaining market share against established players using traditional materials.

What Could Drive SINT Stock Higher?

SINT catalyst: Successful achievement of regulatory approvals for new silicon nitride-based medical device applications, opening new market segments.

• Announcement of strategic partnerships or licensing agreements with larger medical device companies to expand distribution and market reach.
• Publication of positive clinical data demonstrating superior outcomes, such as reduced infection rates, for silicon nitride implants compared to traditional materials.
• Expansion of the product portfolio with new forms of silicon nitride or composite materials targeting high-value industrial applications.
• Significant increase in market adoption and sales volume of existing silicon nitride products, indicating growing acceptance by surgeons and healthcare systems.

What Are the Key Risks for SINT?

Financial-distress signal — its Altman Z-Score of -41.81 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Failure to secure necessary regulatory approvals for new silicon nitride products, hindering market entry and commercialization efforts.
• Intense competition from established medical device manufacturers using traditional materials, making market share gains challenging.
• Significant financial losses and negative margins (-1711.6% profit margin, -32.7% gross margin) indicating ongoing operational challenges and potential need for further capital.
• Market resistance or slow adoption of new biomaterials by surgeons and healthcare systems accustomed to traditional implant materials.
• Dependence on a single core material, silicon nitride, which could pose risks if alternative, superior materials emerge or if supply chain disruptions occur.

What Are the Growth Opportunities for SINT?

• Growth opportunity 1: Expansion into Advanced Orthopedic and Spinal Implants. Sintx Technologies' primary focus on silicon nitride for orthopedic and spinal implants represents a significant growth driver. Silicon nitride's unique combination of strength, biocompatibility, and inherent antibacterial properties offers a compelling alternative to traditional materials like titanium and PEEK. By demonstrating superior clinical outcomes, particularly in reducing post-operative infection rates, Sintx can capture market share and establish its silicon nitride products as a preferred material choice within a 5-10 year timeline.
• Growth opportunity 2: Diversification into Broader Antipathogenic Applications. Beyond traditional implants, the inherent antibacterial properties of silicon nitride open avenues for broader antipathogenic applications. This could include developing coatings for a wider range of medical instruments, creating antimicrobial surfaces for healthcare environments, or even integrating silicon nitride into consumer products where infection control is critical. The global market for antimicrobial coatings is expanding rapidly, driven by heightened awareness of healthcare-associated infections and public health concerns. This diversification could unlock multi-billion dollar opportunities over the next decade, leveraging the company's core material science expertise into new, high-growth segments.
• Growth opportunity 3: Penetration of High-Performance Industrial Markets. While primarily focused on biomedical applications, Sintx Technologies' silicon nitride materials also possess properties suitable for demanding industrial uses. Silicon nitride is known for its exceptional hardness, wear resistance, and thermal stability, making it ideal for components in aerospace, automotive, and semiconductor manufacturing. Expanding into specific, high-value industrial niches that require advanced ceramic materials could provide significant revenue diversification. This strategy would leverage existing material science and manufacturing capabilities, targeting specialized industrial components where performance requirements justify premium materials, with a potential market impact within a 3-7 year timeframe.
• Growth opportunity 4: Development of Advanced Composite Materials. The company's capability in developing advanced silicon nitride composite materials and polyetherketoneketone (PEKK) allows for the creation of products with highly tailored properties. This enables Sintx to address complex engineering challenges and develop next-generation materials that offer enhanced performance characteristics for both existing and emerging markets. The global advanced composites market is a multi-trillion dollar industry, with continuous demand for lighter, stronger, and more durable materials across various sectors. By innovating in composite formulations, Sintx can carve out high-value segments, offering customized solutions that command premium pricing and expand its intellectual property portfolio over the long term.
• Growth opportunity 5: Strategic Partnerships and Licensing Agreements. Collaborating with larger, established medical device manufacturers or industrial conglomerates could significantly accelerate market penetration and product adoption for Sintx Technologies. Licensing its proprietary silicon nitride technology to companies with extensive distribution networks, robust manufacturing capabilities, or complementary product lines would provide a capital-efficient growth pathway. Such strategic partnerships could unlock substantial market potential, particularly in specialized medical or high-tech industrial sectors, within a 2-5 year timeframe. These alliances could also validate the technology and provide crucial funding for further research and development, mitigating some of the financial risks associated with independent commercialization.

What Threats Does SINT Face?

• Intense competition from established medical device manufacturers utilizing traditional materials.
• Rigorous and lengthy regulatory approval processes for new medical devices.
• High capital requirements for research, development, and commercialization of advanced materials.
• Potential for new material innovations from competitors that could diminish silicon nitride's competitive edge.

What Are SINT's Competitive Advantages?

• Proprietary expertise and intellectual property in silicon nitride material science and manufacturing processes.
• Unique material properties of silicon nitride, including inherent antibacterial characteristics, offering a differentiated product in the medical device market.
• Specialized product portfolio including solid, porous, powder, and composite forms of silicon nitride, catering to diverse applications.
• Early mover advantage in commercializing silicon nitride for specific biomedical applications, particularly in orthopedics.
• Regulatory approvals and clinical data supporting the safety and efficacy of silicon nitride products, once obtained, would create significant barriers to entry.

What Does SINT Do?

Sintx Technologies, Inc., established in 1996 and formerly known as Amedica Corporation, is an advanced materials enterprise headquartered in Salt Lake City, Utah. The company is dedicated to the comprehensive research, development, and commercialization of medical devices primarily crafted from silicon nitride. This innovative material forms the core of its product portfolio, which is designed to serve a diverse range of applications, including biomedical, industrial, and antipathogenic uses, predominantly marketed across the United States. Sintx Technologies' offerings are extensive, encompassing various forms of silicon nitride, such as solid and porous structures, as well as silicon nitride powder. Beyond these foundational materials, the company also develops specialized coating products that enhance the functionality and performance of medical devices. Furthermore, its expertise extends to advanced silicon nitride composite materials and polyetherketoneketone (PEKK), enabling the creation of highly specialized solutions for demanding applications. The company's strategic focus on advanced biomaterials, particularly for orthopedic and spinal implants, leverages silicon nitride's inherent antibacterial properties, which present a potential advantage in reducing infection rates in medical settings. With its deep roots in material science and a commitment to innovation, Sintx Technologies aims to address critical needs in healthcare and high-performance industrial sectors through its proprietary silicon nitride technology.

What Products and Services Does SINT Offer?

• Researches, develops, and commercializes medical devices made from silicon nitride.
• Focuses on advanced biomaterials for orthopedic and spinal implants.
• Produces solid silicon nitride for various applications.
• Manufactures porous silicon nitride products.
• Develops and supplies silicon nitride powder.
• Creates specialized coating products utilizing silicon nitride.
• Works with advanced silicon nitride composite materials.
• Utilizes polyetherketoneketone (PEKK) in its material science endeavors.
• Markets its products primarily across the United States for biomedical, industrial, and antipathogenic uses.

How Does SINT Make Money?

• Sells silicon nitride-based medical devices and materials directly to healthcare providers and potentially through distributors in the United States.
• Generates revenue from the commercialization of solid and porous silicon nitride products for biomedical applications.
• Offers silicon nitride powder and specialized coating products to industrial and medical device manufacturers.
• Develops and sells advanced silicon nitride composite materials and PEKK for specialized high-performance applications.
• Potential for licensing intellectual property related to silicon nitride technology to other manufacturers.

What Industry Does SINT Operate In?

Sintx Technologies operates within the highly specialized and competitive Medical Devices industry, a segment of the broader Healthcare sector. This industry is characterized by rigorous regulatory requirements, continuous technological advancements, and a strong emphasis on patient safety and efficacy. The global medical devices market is experiencing steady growth, driven by an aging population, increasing prevalence of chronic diseases, and innovations in biomaterials and surgical techniques. Sintx Technologies distinguishes itself by focusing on silicon nitride, an advanced ceramic material, for orthopedic and spinal implants. While traditional materials like titanium, cobalt-chrome, and PEEK (polyether ether ketone) dominate the market, silicon nitride offers unique properties, including inherent antibacterial characteristics and excellent biocompatibility. The company's positioning is at the forefront of biomaterial innovation, aiming to disrupt established segments by offering superior infection control and biomechanical performance. Success hinges on demonstrating clear clinical advantages and navigating the competitive landscape dominated by larger, diversified medical device manufacturers.

Who Are SINT's Key Customers?

• Hospitals and surgical centers requiring orthopedic and spinal implants.
• Medical device manufacturers seeking advanced biomaterials and coatings.
• Industrial companies requiring high-performance ceramic materials for specialized applications.
• Research institutions and academic partners for material science development.
• Potentially, other industries with needs for antipathogenic surfaces or components.

Company Profile

Sintx Technologies, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Salt Lake City, US. The company is led by CEO Eric K. Olson. SINT has traded publicly since 2014.

How Sintx Technologies, Inc. Is Valued

Sintx Technologies, Inc. carries a market capitalization of $9.60M, placing it in the micro-cap category. Relative to its peer group, SINT's quantitative score of 21/100 is below the peer average of 65/100.

Sintx Technologies, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -41.81 places it in the distress zone, a signal of elevated financial risk.

Wall Street analysts project Sintx Technologies, Inc. revenue of about $2.3M for fiscal 2026, with EPS near $-2.13.

SINT Financials

SINT Latest News

No recent news available for SINT.

SINT Analyst Consensus

SINT MoonshotScore

SINT Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources